{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Fowlpox-GM-CSF", "query": { "intervention": "Recombinant Fowlpox-GM-CSF" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Fowlpox-GM-CSF&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-12T21:08:13.194Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00045227", "title": "Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "recombinant fowlpox-prostate specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia prostate-specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-B7.1 vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "2002-08", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045227" }, { "nct_id": "NCT00048893", "title": "Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms", "Metastases, Neoplasm" ], "interventions": [ { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2002-11", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2012-04-13", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Hackensack, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048893" }, { "nct_id": "NCT00108732", "title": "A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Prostate Carcinoma", "Stage I Prostate Cancer", "Stage IIA Prostate Cancer", "Stage IIB Prostate Cancer", "Stage III Prostate Cancer" ], "interventions": [ { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant Vaccinia-TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2006-02", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2015-06-30", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 7, "location_summary": "Jacksonville, Florida • Chicago, Illinois • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108732" }, { "nct_id": "NCT00081848", "title": "Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Neoplasms" ], "interventions": [ { "name": "rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM", "type": "DRUG" }, { "name": "rF-CEA(6D)/TRICOM", "type": "DRUG" }, { "name": "Recombinant Fowlpox-GM-CSF", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2004-04-20", "completion_date": "2007-08-23", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081848" }, { "nct_id": "NCT00020254", "title": "Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox-prostate specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia prostate-specific antigen vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-B7.1 vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "nilutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020254" }, { "nct_id": "NCT00060528", "title": "Sequential Vaccinations in Prostate Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Recombinant Fowlpox-GM-CSF", "type": "DRUG" }, { "name": "Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)", "type": "DRUG" }, { "name": "Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)", "type": "DRUG" }, { "name": "Recombinant Human GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2003-05-22", "completion_date": "2009-06-08", "has_results": true, "last_update_posted_date": "2017-10-26", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060528" }, { "nct_id": "NCT00450619", "title": "153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Samarium Sm 153 lexidronam pentasodium", "type": "RADIATION" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Recombinant vaccinia-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant fowlpox-TRICOM vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 44, "start_date": "2007-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 3, "location_summary": "Chicago, Illinois • Bethesda, Maryland • New Brunswick, New Jersey", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450619" }, { "nct_id": "NCT00009958", "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-CEA(6D)-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-16", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00009958" }, { "nct_id": "NCT00217373", "title": "Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" }, { "name": "Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2005-06", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2015-04-20", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217373" }, { "nct_id": "NCT00096551", "title": "A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)", "type": "DRUG" }, { "name": "Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)", "type": "DRUG" }, { "name": "Recombinant Fowlpox-GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 21, "start_date": "2004-11-01", "completion_date": "2011-07-25", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-12T21:08:13.194Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096551" } ] }